Page 6«..5678..2030..»

Orca Bio Presents Promising Data on Orca-T in Two Oral Presentations at the 2024 Tandem Meetings of ASTCT and … – Yahoo Finance

By daniellenierenberg

Orca Bio Presents Promising Data on Orca-T in Two Oral Presentations at the 2024 Tandem Meetings of ASTCT and ...  Yahoo Finance

Excerpt from:
Orca Bio Presents Promising Data on Orca-T in Two Oral Presentations at the 2024 Tandem Meetings of ASTCT and ... - Yahoo Finance

To Read More: Orca Bio Presents Promising Data on Orca-T in Two Oral Presentations at the 2024 Tandem Meetings of ASTCT and … – Yahoo Finance
categoriaBone Marrow Stem Cells commentoComments Off on Orca Bio Presents Promising Data on Orca-T in Two Oral Presentations at the 2024 Tandem Meetings of ASTCT and … – Yahoo Finance | dataFebruary 24th, 2024
Read All

AJMC in the Press, February 23, 2024 – AJMC.com Managed Markets Network

By daniellenierenberg

AJMC in the Press, February 23, 2024  AJMC.com Managed Markets Network

Read more:
AJMC in the Press, February 23, 2024 - AJMC.com Managed Markets Network

To Read More: AJMC in the Press, February 23, 2024 – AJMC.com Managed Markets Network
categoriaBone Marrow Stem Cells commentoComments Off on AJMC in the Press, February 23, 2024 – AJMC.com Managed Markets Network | dataFebruary 24th, 2024
Read All

Expanding the Horizons of Cell and Gene Therapy – RegMedNet

By daniellenierenberg

Expanding the Horizons of Cell and Gene Therapy  RegMedNet

Read the original:
Expanding the Horizons of Cell and Gene Therapy - RegMedNet

To Read More: Expanding the Horizons of Cell and Gene Therapy – RegMedNet
categoriaBone Marrow Stem Cells commentoComments Off on Expanding the Horizons of Cell and Gene Therapy – RegMedNet | dataFebruary 24th, 2024
Read All

If Other Treatments Aren’t Working — Stem Cell Transplant May Be A Good Option In CLL – SurvivorNet

By daniellenierenberg

If Other Treatments Aren't Working -- Stem Cell Transplant May Be A Good Option In CLL  SurvivorNet

Continued here:
If Other Treatments Aren't Working -- Stem Cell Transplant May Be A Good Option In CLL - SurvivorNet

To Read More: If Other Treatments Aren’t Working — Stem Cell Transplant May Be A Good Option In CLL – SurvivorNet
categoriaBone Marrow Stem Cells commentoComments Off on If Other Treatments Aren’t Working — Stem Cell Transplant May Be A Good Option In CLL – SurvivorNet | dataFebruary 24th, 2024
Read All

The strangers who saved each others lives – BBC

By daniellenierenberg

The strangers who saved each others lives  BBC

View original post here:
The strangers who saved each others lives - BBC

To Read More: The strangers who saved each others lives – BBC
categoriaBone Marrow Stem Cells commentoComments Off on The strangers who saved each others lives – BBC | dataFebruary 24th, 2024
Read All

Moving Forward: Stem Cells in the Treatment of Spinal Cord Injuries – Corporate Wellness Magazine

By daniellenierenberg

Moving Forward: Stem Cells in the Treatment of Spinal Cord Injuries  Corporate Wellness Magazine

Read more here:
Moving Forward: Stem Cells in the Treatment of Spinal Cord Injuries - Corporate Wellness Magazine

To Read More: Moving Forward: Stem Cells in the Treatment of Spinal Cord Injuries – Corporate Wellness Magazine
categoriaSpinal Cord Stem Cells commentoComments Off on Moving Forward: Stem Cells in the Treatment of Spinal Cord Injuries – Corporate Wellness Magazine | dataFebruary 24th, 2024
Read All

Statement of Renovaro Inc

By Dr. Matthew Watson

LOS ANGELES, Feb. 14, 2024 (GLOBE NEWSWIRE) -- The following is a statement by Renovaro (Nasdaq: RENB) in response to Hindenburg's recent opinion piece:

Go here to see the original:
Statement of Renovaro Inc

To Read More: Statement of Renovaro Inc
categoriaGlobal News Feed commentoComments Off on Statement of Renovaro Inc | dataFebruary 15th, 2024
Read All

Genmab Publishes 2023 Annual Report

By Dr. Matthew Watson

Company Announcement

View original post here:
Genmab Publishes 2023 Annual Report

To Read More: Genmab Publishes 2023 Annual Report
categoriaGlobal News Feed commentoComments Off on Genmab Publishes 2023 Annual Report | dataFebruary 15th, 2024
Read All

Hyloris Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures

By Dr. Matthew Watson

Liège, Belgium – February, 14 2024 – 6PM CET – Non-regulated information - Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that the first patient has been enrolled in a pivotal Phase 3 clinical trial for Tranexamic Acid Oral Rinse.

See more here:
Hyloris Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures

To Read More: Hyloris Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures
categoriaGlobal News Feed commentoComments Off on Hyloris Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures | dataFebruary 15th, 2024
Read All

Fresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15th

By Dr. Matthew Watson

Stockholders of record on January 11, 2024 who have not yet voted are encouraged to do so by 11:59 p.m. Eastern Time on February 14, 2024

Read the rest here:
Fresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15th

To Read More: Fresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15th
categoriaGlobal News Feed commentoComments Off on Fresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15th | dataFebruary 15th, 2024
Read All

Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference

By Dr. Matthew Watson

HANOVER, MD, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, announces that CEO George Ng will present a corporate update at The Winter Wrap-Up MicroCap Rodeo 2024 Virtual Conference being held February 20 – 23, 2024.

See more here:
Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference

To Read More: Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference
categoriaGlobal News Feed commentoComments Off on Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference | dataFebruary 15th, 2024
Read All

Starton Therapeutics Announces Opening of Second Clinical Site for STAR-LLD Phase 1b Trial in Multiple Myeloma and Provides Study Update

By Dr. Matthew Watson

PARAMUS, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton” or “the Company”), a clinical-stage biotechnology company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, announced Regional Medical Oncology Center (RMOC) in Wilson, NC as the second site activated in the STAR-LLD Phase 1b clinical trial. The ongoing study evaluates the safety, pharmacokinetics, and efficacy of continuous subcutaneous administration of low-dose lenalidomide (STAR-LLD) in conjunction with dexamethasone and bortezomib (Velcade®). Remarkably, the trial is progressing ahead of schedule and with the addition of RMOC is now projected to conclude enrollment by Q1/2024.

Read more from the original source:
Starton Therapeutics Announces Opening of Second Clinical Site for STAR-LLD Phase 1b Trial in Multiple Myeloma and Provides Study Update

To Read More: Starton Therapeutics Announces Opening of Second Clinical Site for STAR-LLD Phase 1b Trial in Multiple Myeloma and Provides Study Update
categoriaGlobal News Feed commentoComments Off on Starton Therapeutics Announces Opening of Second Clinical Site for STAR-LLD Phase 1b Trial in Multiple Myeloma and Provides Study Update | dataFebruary 15th, 2024
Read All

Genmab Files Annual Report with the U.S. Securities and Exchange Commission

By Dr. Matthew Watson

Media Release COPENHAGEN, Denmark; February 14, 2024

More:
Genmab Files Annual Report with the U.S. Securities and Exchange Commission

To Read More: Genmab Files Annual Report with the U.S. Securities and Exchange Commission
categoriaGlobal News Feed commentoComments Off on Genmab Files Annual Report with the U.S. Securities and Exchange Commission | dataFebruary 15th, 2024
Read All

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024

By Dr. Matthew Watson

SAN DIEGO, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, after the close of the U.S. financial markets. Company management will host a conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a business update.

See the article here:
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024

To Read More: Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
categoriaGlobal News Feed commentoComments Off on Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 | dataFebruary 15th, 2024
Read All

Celularity’s Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell…

By Dr. Matthew Watson

-Highlights potential uses of Celularity biomaterials in regenerative medicine applications that combine stem cells and biomaterial scaffolds for use in constructing tissues and for cell delivery

Go here to read the rest:
Celularity’s Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell...

To Read More: Celularity’s Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell…
categoriaGlobal News Feed commentoComments Off on Celularity’s Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell… | dataFebruary 15th, 2024
Read All

Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28

By Dr. Matthew Watson

REDWOOD CITY, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the fourth quarter and fiscal year 2023 on Wednesday, February 28, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update.

Visit link:
Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28

To Read More: Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28
categoriaGlobal News Feed commentoComments Off on Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28 | dataFebruary 15th, 2024
Read All

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results

By Dr. Matthew Watson

SEATTLE, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2023.

More here:
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results

To Read More: Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results
categoriaGlobal News Feed commentoComments Off on Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results | dataFebruary 15th, 2024
Read All

Cronos Group Inc. to Hold 2023 Fourth Quarter and Full-Year Earnings Conference Call on February 29, 2024

By Dr. Matthew Watson

TORONTO, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2023 fourth quarter and full-year earnings conference call on Thursday, February 29, 2024 at 8:30 a.m. ET. Cronos’ senior management team will discuss the Company’s financial results and will be available for questions from the investment community after prepared remarks.

Here is the original post:
Cronos Group Inc. to Hold 2023 Fourth Quarter and Full-Year Earnings Conference Call on February 29, 2024

To Read More: Cronos Group Inc. to Hold 2023 Fourth Quarter and Full-Year Earnings Conference Call on February 29, 2024
categoriaGlobal News Feed commentoComments Off on Cronos Group Inc. to Hold 2023 Fourth Quarter and Full-Year Earnings Conference Call on February 29, 2024 | dataFebruary 15th, 2024
Read All

Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients…

By Dr. Matthew Watson

- Presentations will Highlight Initial Data Announced in January 2024 Demonstrating Proof-of-Concept in its DM1 and DMD Programs, Validating the Promise of the FORCE™ Platform and Targeted Delivery to Muscle -

See the original post:
Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients...

To Read More: Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients…
categoriaGlobal News Feed commentoComments Off on Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients… | dataFebruary 15th, 2024
Read All

NurExone Launches Licensing Efforts for ExoTherapy Platform

By Dr. Matthew Watson

Huge opportunity for development of nanodrugs for wide variety of clinical indications Huge opportunity for development of nanodrugs for wide variety of clinical indications

Here is the original post:
NurExone Launches Licensing Efforts for ExoTherapy Platform

To Read More: NurExone Launches Licensing Efforts for ExoTherapy Platform
categoriaGlobal News Feed commentoComments Off on NurExone Launches Licensing Efforts for ExoTherapy Platform | dataFebruary 15th, 2024
Read All

Page 6«..5678..2030..»


Copyright :: 2024